Huimin Liu, Furong Kou, Li Hu, Jie Sun, Juan Zhang, Ye Xu 1, Lu Yao, Yuntao Xie*.Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy.,Breast Cancer Res Treat,2025;211(3):705-715

Jie Sun, Lu Yao, Jiuan Chen, Li Hu, Juan Zhang, Ye Xu, Yuntao Xie*. Predicting the likelihood of BRCA1/2 germline pathogenic variants in unselected patients with breast cancer: analysis of more than 10,000 individuals.,J Med Genet,2025;62(2):62-68

Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang*, Yuntao Xie*.Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.,Breast Cancer Res Treat.,208(1):155-164

Jie Sun, Futao Chu, Jiani Pan, Yaxin Zhang, Lu Yao, Jiuan Chen, Li Hu, Juan Zhang, Ye Xu, Xiaojia Wang, Wenming Cao, Yuntao Xie. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers,J Clin Oncol,41(5):991-999

Fan Zang, Xinyun Ding, Jiuan Chen, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Lu Yao, Yuntao Xie*. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype,Breast cancer research and treatment,195: 431-9

Lu Yao, Jie Sun , Li Hu, Jiuan Chen, Juan Zhang, Ye Xu, Yuntao Xie. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants,Journal of human genetics,67(11)：639-642

Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.,Cancer Res,81(10):2600-2611

Xue Yu, Furong Kou, Yuntao Xie*. Attitude towards genetic testing for breast cancer susceptibility genes and choice of prevention strategies in Chinese women with or without breast cancer.,Cancer Biol M,2025;22(1):28-32

Yonghai Guo, Qiting Wan, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Yuntao Xie. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients,Breast,10;65: 55-60

Jingsi Liu, Jiuan Chen, Jie Sun, Lu Yao, Juan Zhang, Yuntao Xie, Ye Xu. Low Expression of PALB2 is Associated With Poor Survival in Chinese Women With Primary Breast Cancer,Clin Breast Cancer,2023 Jun;23(4):e259-e266

Jiaming Liu, Lu Yao, Jie Sun, Li Hu, Jiuan Chen, Juan Zhang, Ye Xu, Yuntao Xie. Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer,Cancer Biol Med,20(2):147-154

Xuejing Liu, Yanjie Wang, Kun Cao, Lu Yao, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Yuntao Xie. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants,Breast Cancer Res Treat.,199(1):25-33.

Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.,Int J Cancer,148(4):941-949

Furong Kou, Huimin Liu, Yaxin Zhang, Xingyu Liao, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Lu Yao, Yuntao Xie*. Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2-Low Tumors in BRCA1/2-Mutated Triple-Negative Breast Cancer.,JCO Precis Oncol,2025:e2400679

Li Hu, Jie Sun, Zhongwu Li, Ziwei Qu, Yan Liu, Qiting Wan, Jiaming Liu, Xinyun Ding, Fan Zang, Juan Zhang, Lu Yao, Ye Xu, Yin Wang, and Yuntao Xie*. Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients,NPJ breast cancer,8: 52

Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.,JAMA Netw Open,4(4):e216259

乳腺癌个体化治疗

BRCA1/2胚系突变遗传性乳腺癌早期发生的分子机制及可视化研究, 课题负责人, 2024.1.1～2026.12.31, 国自然重大研究计划重点支持项目

BRCA1胚系突变乳腺癌的发生机制及早期预警靶点, 课题负责人, 2023.1.1～2026.12.31, 国自然面上项目

乳腺癌易感基因RECQL致瘤机制及潜在分子靶点的研究, 课题负责人, 2020.1.1～2023.12.31, 国家自然科学基金委员会面上项目